Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Imifoplatin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PT-112 is under development for the treatment of advanced solid tumors including squamous or non-squamous non small cell lung cancer (NSCLC), basal cell carcinoma, pancreatic cancer, ovarian cancer, gallbladder cancer, gastric cancer, cholangiocarcinoma, colorectal cancer, thymoma, thymic carcinoma, neuroendocrine carcinoma, intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), metastatic hepatocellular carcinoma, urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (SCCHN), castration-resistant prostate cancer (CRPC), breast cancer, liver cancer or hepatic metastasis and relapsed or refractory multiple myeloma. The drug candidate is administered intravenously. It is a phosphaplatin which is a combination of phosphate and platinum.
Promontory Therapeutics overview
Promontory Therapeutics formerly Phosplatin Therapeutics LLC, is a clinical stage pharmaceutical company developing phosphaplatins, a family of novel anti cancer small molecule agents. Its lead product candidate PT-112, is a pyrophosphate conjugated platinum therapeutic agent that combines apoptotic and immunogenic properties for preventing solid tumors and hematological malignancies. Promontory Therapeutics works in collaboration with various contract research organizations, pharmaceutical companies and universities to study the mechanism of action of its lead drug candidate. The company markets its products through its network of distributors across the US. Promontory Therapeutics is headquartered in New York City, New York, the US.
For a complete picture of Imifoplatin’s drug-specific PTSR and LoA scores, buy the report here.